Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $44.00

Dianthus Therapeutics (NASDAQ:DNTH) had its price target hoisted by Wedbush from $42.00 to $44.00 in a research report released on Friday,Benzinga reports. Wedbush currently has an outperform rating on the stock.

Several other equities research analysts have also commented on the stock. Guggenheim boosted their price target on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, September 9th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, September 8th. William Blair began coverage on Dianthus Therapeutics in a report on Wednesday, July 2nd. They set an “outperform” rating for the company. Robert W. Baird lifted their price target on Dianthus Therapeutics from $50.00 to $67.00 and gave the company an “outperform” rating in a report on Tuesday, September 9th. Finally, Raymond James Financial restated an “outperform” rating and set a $63.00 price objective (up from $56.00) on shares of Dianthus Therapeutics in a research note on Tuesday, September 9th. Nine research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $61.57.

Dianthus Therapeutics Trading Down 1.8%

Shares of DNTH stock opened at $37.16 on Friday. Dianthus Therapeutics has a twelve month low of $13.36 and a twelve month high of $38.59. The stock has a fifty day simple moving average of $23.01 and a two-hundred day simple moving average of $20.53. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -11.43 and a beta of 1.46.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.87 million. Research analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Ryan Savitz sold 20,000 shares of the stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total value of $700,000.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 16.56% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

Large investors have recently made changes to their positions in the business. Raymond James Financial Inc. purchased a new position in shares of Dianthus Therapeutics during the second quarter worth $27,000. US Bancorp DE boosted its holdings in Dianthus Therapeutics by 2,013.3% in the first quarter. US Bancorp DE now owns 1,585 shares of the company’s stock valued at $29,000 after purchasing an additional 1,510 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in Dianthus Therapeutics during the 4th quarter worth about $59,000. GAMMA Investing LLC raised its stake in shares of Dianthus Therapeutics by 3,030.6% during the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock valued at $70,000 after buying an additional 3,758 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after buying an additional 3,317 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.